Concepedia

Raul Ayala

RA

Statistics

Publications

10

Citations

1K

H-Index

10

Active since

2003

Affiliations

University of California, Los Angeles(Current)

Novartis (Switzerland)

Raul Ayala is an author at University of California, Los Angeles specializing in oncology, medicine, and pharmacology.

Publications per year

2003–2023

10

Publications

10

Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

M. Jane Arboleda, John F. Lyons, Fairooz F. Kabbinavar et al. · PubMed · 2003 · 422 citations

Medicine, Cancer Biology, Oncology +17

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <i>In vitro</i> and <i>In vivo</i>

Zev A. Wainberg, Adrian Anghel, Amrita Desai et al. · Clinical Cancer Research · 2010 · 211 citations

Medicine, Oncology, Pharmacology +16

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin et al. · Breast Cancer Research · 2020 · 156 citations · Full text

Medicine, Oncology, Pharmacology +16

Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells

Gottfried E. Konecny, Teodora Kolarova, Neil A. O’Brien et al. · Molecular Cancer Therapeutics · 2013 · 73 citations

Medicine, Oncology, Pharmacology +17

Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

Zev A. Wainberg, Adrian Anghel, Amy M. Rogers et al. · Molecular Cancer Therapeutics · 2013 · 68 citations

Medicine, Oncology, Pharmacology +16

1–5 of 10